Innoviva, Inc. (INVA) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-02-25

Business type: Franchise

How it makes money

It earns revenue from royalties paid by GSK on partnered respiratory drugs and from direct sales of hospital-focused critical care products.

It collects tiered royalties under its agreement with Glaxo Group Limited for respiratory medicines like RELVAR/BREO ELLIPTA and ANORO ELLIPTA, receiving 15% on the first $3.0 billion of annual global net sales and 5% for sales above $3.0 billion, alongside upward-tiering royalties ranging from 6.5% to 10% for ANORO. In addition, it generates net product sales from its wholly owned critical care and infectious disease platform, Innoviva Specialty Therapeutics, which includes commercialized hospital products such as GIAPREZA, XACDURO, XERAVA, ZEVTERA, and NUZOLVENCE.

The primary variables moving profit are the global net sales volume achieved by GSK for the partnered respiratory inhalers and the commercial adoption rate and sales growth of its proprietary hospital-focused infectious disease and critical care portfolio.

What protects it: the moat

It relies on patent-protected pharmaceutical formulations and partnered commercial agreements, though management notes competition and third-party dependencies pose ongoing challenges.

Protection for its cash flows stems from exclusive licensing arrangements, regulatory approvals for specialized hospital drugs, and long-standing collaboration agreements governing its respiratory portfolio. However, management discloses that these positions face substantial competitive threats from branded and generic alternatives marketed by major pharmaceutical companies.

Management's claims of market exclusivity and competitive advantage are tempered by disclosures that rivals can develop competing therapies, and that it lacks direct control over the commercialization efforts and sales execution deployed by its primary partner, GSK.

What could damage it

If GSK reduces its commercial support or reprioritizes its own non-partnered products, royalty revenues could fall and permanently impair earnings.

Because it relies heavily on GSK to drive the global sales of its partnered respiratory medications, any strategic shift by GSK away from these programs directly impacts top-line royalty collections. If GSK cuts marketing budgets, fails to expand product indications, or prioritizes competing proprietary drugs not partnered with it, the resulting drop in royalty generation would diminish cash flows without any operational recourse available to it.

About Innoviva, Inc.

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Other companies in Biotechnology